Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

被引：16
|
作者：
Andre, F. [1 ]
Nadal, J. C. [2 ]
Denys, H. [3 ]
Goel, S. [4 ]
Litchfield, L. M. [5 ]
Appiah, A. [5 ]
Chen, Y. [5 ]
Tolaney, S. M. [6 ]
机构：
[1] Gustave Roussy Canc Campus, Dept Med Oncol, Breast Canc Unit, Villejuif, France
[2] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina
[3] Univ Ziekenhuis Gent, Dept Med Oncol, Ghent, Belgium
[4] Peter MacCallum Canc Ctr, Dept Canc Res, Melbourne, Vic, Australia
[5] Eli Lilly & Co Global Headquarters, Oncol, Indianapolis, IN USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA18
引用
收藏
页码：S1386 / S1387
页数：2
相关论文
共 50 条
  • [1] Monarcher: A Randomized Phase 2 Study of Abemaciclib Plus Trastuzumab with or without Fulvestrant Versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women with HR+, HER2+Advanced Breast Cancer
    Ettl, Johannes
    Tolaney, Sara
    Wardley, Andrew
    Zambelli, Stefania
    Hilton, John F.
    Ricci, Francesco
    Im, Seock-Ah
    Kim, Sung-Bae
    Johnston, Stephen
    Chan, Arlene
    Goel, Shom
    Catron, Kristen
    Yang, Zhengyu
    Gainford, Corona
    Andre, Fabrice
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 16 - 16
  • [2] MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+advanced breast cancer (ABC)
    Tolaney, S. M.
    Wardley, A. M.
    Zambelli, S.
    Hilton, J.
    Troso-Sandoval, T.
    Ricci, F.
    Im, S-A.
    Kim, S-B.
    Johnston, S. R. D.
    Chan, A.
    Goel, S.
    Catron, K.
    Yang, Z.
    Gainford, C.
    Andre, F.
    ANNALS OF ONCOLOGY, 2019, 30 : 861 - +
  • [3] Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+advanced breast cancer: plain language summary of the monarcHER study
    Tolaney, Sara M.
    Goel, Shom
    Appiah, Adams Kusi
    Huynh, Trish
    Chen, Yanyun
    Andre, Fabrice
    FUTURE ONCOLOGY, 2023, 19 (35) : 2341 - 2348
  • [4] Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+advanced breast cancer
    Tolaney, Sara M.
    Wardley, Andrew M.
    Zambelli, Stefania
    Hilton, John F.
    Troso-Sandoval, Tiffany A.
    Ricci, Francesco
    Im, Seock-Ah
    Kim, Sung-Bae
    Johnston, Stephen R. D.
    Chan, Arlene
    Goel, Shom
    Catron, Kristen
    Yang, Zhengyu
    Gianford, M. Corona
    Price, Gregory L.
    Andre, Fabrice
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+Metastatic Breast Cancer Patients
    Tolaney, Sara M.
    Goel, Shom
    Nadal, Jorge
    Denys, Hannelore
    Borrego, Manuel R.
    Litchfield, Lacey M.
    Liu, Jiangang
    Appiah, Adams K.
    Chen, Yanyun
    Andre, Fabrice
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 39 - 49
  • [6] monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+advanced breast cancer
    Tolaney, S. M.
    Bourayou, N.
    Goel, S.
    Forrester, T.
    Andre, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
    Tolaney, Sara M.
    Wardley, Andrew M.
    Zambelli, Stefania
    Hilton, John F.
    Troso-Sandoval, Tiffany A.
    Ricci, Francesco
    Im, Seock-Ah
    Kim, Sung-Bae
    Johnston, Stephen R. D.
    Chan, Arlene
    Goel, Shom
    Catron, Kristen
    Chapman, Sonya C.
    Price, Gregory L.
    Yang, Zhengyu
    Gainford, M. Corona
    Andre, Fabrice
    LANCET ONCOLOGY, 2020, 21 (06): : 763 - 775
  • [8] A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarcHER)
    Tolaney, Sara M.
    Bourayou, Nawel
    Goel, Shorn
    Hossain, Anwar
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [10] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
    Grischke, Eva Maria
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Masuda, Norikazu
    Kaufman, Peter
    Koh, Han
    Conte, Pierfranco
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
12345